Compare AU
Compare DRUG vs. IISV
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare Currency Hedged ETF (DRUG) and the Intell Investor Select Value Shr Fund - Active ETF (IISV). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | IISV | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 61 | 11 |
Median incremental investment | $920.50 | $665.13 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,892.10 | $4,559.49 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
DRUG | IISV | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | IISV.AX was created on 2023-03-31 by Intelligent Investor . The fund's investment portfolio concentrates primarily on total market equity. The portfolio aims to outperform the S&P/ASX 200 Accumulation Index p.a. over five year rolling periods with minimal turnover to allow returns to compound in a favourable tax environment |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | RPMGlobal Holdings Ltd (7.77 %) Fairfax Financial Holdings Ltd Shs Subord.Vtg (6.95 %) KKR & Co Inc Ordinary Shares (5.57 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | Financials (50.65 %) Consumer Discretionary (15.93 %) Information Technology (14.85 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | United States (42.65 %) Australia (20.03 %) United Kingdom of Great Britain and Northern Ireland (15.60 %) |
Management fee | 0.57 % | 0.97 % |
Key Summary
DRUG | IISV | |
|---|---|---|
Issuer | BetaShares | Intelligent Investor |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | S&P/ASX 200 Accumulation Index - AUD - Benchmark TR Net |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.97 % |
Price | $7.95 | $3.51 |
Size | $185.172 million | N/A |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.90 % | 0.07 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 30/03/2023 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | IISV | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 61 | 11 |
Median incremental investment | $920.50 | $665.13 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,892.10 | $4,559.49 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
DRUG | IISV | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | IISV |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |